Pipeline

Pioneering Treg-Targeted Therapies

Our broad pipeline combines three therapeutic modalities targeting Treg dysfunction:
Treg modifying biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy.

COYA 302 Program

Additional Pipeline Assets

Coya is currently enrolling the ALSTARS Phase 2 trial for Coya 302 for people living with ALS across the U.S. and Canada. More information about the ALSTARS trial is available on https://clinicaltrials.gov/study/NCT07161999 or https://trials.coyatherapeutics.com/